SCHEMBL20938261

SCHEMBL20938261

COc1cc(-c2cn([C@@H]3O[C@H](CO)C[C@H]3O)c3ncnc(N)c23)ccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 5/20 0.57
▸ KIF5B P33176 5/20 0.57
▸ ABL1 P00519 4/20 0.49
▸ EGFR P00533 3/20 0.49
▸ ABL2 P42684 3/20 0.49
▸ KDR P35968 6/20 0.48
▸ KCNH2 Q12809 2/20 0.48
▸ CCDC6 Q16204 2/20 0.48
▸ ADK P55263 4/20 0.47
▸ SRC P12931 8/20 0.45
▸ LCK P06239 3/20 0.45
▸ TEK Q02763 2/20 0.45
▸ JAK2 O60674 1/20 0.44
▸ NTRK1 P04629 1/20 0.44
▸ INSR P06213 1/20 0.44
▸ NPM1 P06748 1/20 0.44
▸ CSF1R P07333 1/20 0.44
▸ LYN P07948 1/20 0.44
▸ IGF1R P08069 1/20 0.44
▸ MET P08581 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20938267 0.90 ADK (0.49) RETKIF5BABL1EGFRABL2
SCHEMBL20938253 0.90 ADK (0.49) RETKIF5BABL1EGFRABL2
SCHEMBL20938274 0.88 ADK (0.49) RETKIF5BABL1EGFRABL2
SCHEMBL20938345 0.87 PRMT5 (0.47) RETKIF5BABL1EGFRABL2
SCHEMBL20920813 0.86 SRC (0.51) ABL1EGFRABL2KDRADK
SCHEMBL20938250 0.86 SRC (0.51) ABL1EGFRABL2KDRADK
SCHEMBL20938344 0.85 ADK (0.47) RETKIF5BABL1EGFRABL2
SCHEMBL20938251 0.84 RIPK2 (0.56) ABL1EGFRABL2KDRADK
SCHEMBL20938255 0.84 RIPK2 (0.58) RETKIF5BABL1EGFRABL2
SCHEMBL20938268 0.83 ADK (0.50) RETKIF5BABL1EGFRABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections UNIVERSITEIT GENT (BE) 2021-07-27 — — US disclosed
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2021-01-28 — — US disclosed
WO-2019076633-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections PNP, NUDT1, SAMHD1 RET 4645/4885KIF5B 3521/4885ABL1 1044/4885
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS PNP, NUDT1, SAMHD1 RET 4645/4885KIF5B 3521/4885ABL1 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback